Literature DB >> 10580799

Cerebrospinal fluid levels of soluble CD14 in inflammatory and non-inflammatory diseases of the CNS: upregulation during bacterial infections and viral meningitis.

W A Nockher1, M Wick, H W Pfister.   

Abstract

The CD14 antigen, an important cell surface molecule of monocytic cells, is involved in cellular activation: it binds lipopolysaccharide and other cellular lipid structures. Brain macrophages play a pivotal role during inflammatory reactions of the CNS parenchyma, ventricles and meninges. A soluble form of CD14 (sCD14) was measured in paired cerebrospinal fluid (CSF) and serum samples from 91 patients with different neurological diseases. Mean levels of circulating sCD14 in CSF in a control group of 22 patients with neurologic complaints but no neurological deficit on clinical examination were 0.19 +/- 0.06 (mean +/- SD) mg/l. The CSF/blood ratios of sCD14 was 49 +/- 16 x 10(-3), while those of albumin were 4.4 +/- 1.4 x 10(-3). These extremely high CSF/blood ratios of the sCD14 molecule compared to albumin indicate a local cerebral production. No significant changes in CSF sCD14 levels were found in patients with non-inflammatory neurological diseases (NID). In contrast, CSF sCD14 levels were markedly elevated during acute meningitis, but there was no direct correlation between sCD14 and monocyte count in the CSF. Thus, sCD14 could not originate in the CSF compartment from monocytes alone. The highest values for sCD14 were found in CSF during infections with various pathogens such as Staphylococcus aureus or Listeria monocytogenes. While sCD14 serum levels dramatically increased during acute bacterial meningitis, sCD14 ratios did not correlate with albumin ratios during the course of disease. Therefore, increased CSF sCD14 may originate from cerebral production by activated or infiltrated macrophages rather than passive diffusion from the blood, while elevated sCD14 serum levels resulted from enhanced local production. Increased CSF and serum sCD14 values were also observed in meningitis caused by viral infection. As in bacterial meningitis, sCD14 in CSF specimens did not correlate with the function of the blood/CSF barrier. Repeated lumbar punctures revealed a normalization of CSF sCD14 levels during clinical recovery. These results provide the first evidence for local production of sCD14 within the CNS. Our findings further indicate that sCD14 in CSF is a reliable marker for activation of macrophages within the CNS during inflammatory processes.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10580799     DOI: 10.1016/s0165-5728(99)00141-1

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  10 in total

1.  The lipopolysaccharide co-receptor CD14 is present and functional in seminal plasma and expressed on spermatozoa.

Authors:  C L Harris; M A Vigar; J E Rey Nores; V Horejsi; M O Labeta; B P Morgan
Journal:  Immunology       Date:  2001-11       Impact factor: 7.397

2.  CD14 mediates cross talk between mononuclear cells and fibroblasts for upregulation of matrix metalloproteinase 9 by Borrelia burgdorferi.

Authors:  Zhihui Zhao; Rhonda Fleming; Bilaal McCloud; Mark S Klempner
Journal:  Infect Immun       Date:  2007-04-02       Impact factor: 3.441

3.  Diagnostic accuracy of presepsin (sCD14-ST) for prediction of bacterial infection in cerebrospinal fluid samples from children with suspected bacterial meningitis or ventriculitis.

Authors:  David Stubljar; Andreja Natasa Kopitar; Mojca Groselj-Grenc; Kristina Suhadolc; Teja Fabjan; Miha Skvarc
Journal:  J Clin Microbiol       Date:  2015-02-04       Impact factor: 5.948

Review 4.  Soluble CD14: role in atopic disease and recurrent infections, including otitis media.

Authors:  Karin C Lødrup Carlsen; Berit Granum
Journal:  Curr Allergy Asthma Rep       Date:  2007-11       Impact factor: 4.806

5.  Early ART After Cryptococcal Meningitis Is Associated With Cerebrospinal Fluid Pleocytosis and Macrophage Activation in a Multisite Randomized Trial.

Authors:  James E Scriven; Joshua Rhein; Katherine Huppler Hullsiek; Maximilian von Hohenberg; Grace Linder; Melissa A Rolfes; Darlisha A Williams; Kabanda Taseera; David B Meya; Graeme Meintjes; David R Boulware
Journal:  J Infect Dis       Date:  2015-02-04       Impact factor: 5.226

6.  Cerebrospinal Fluid Presepsin As a Marker of Nosocomial Infections of the Central Nervous System: A Prospective Observational Study.

Authors:  Sergey A Abudeev; Kirill V Kiselev; Nikolay M Kruglyakov; Ksenia A Belousova; Inna N Lobanova; Oleg V Parinov; Yuriy D Udalov; Maxim A Zabelin; Alexandr S Samoilov; Evaldas Cesnulis; Tim Killeen; Konstantin A Popugaev
Journal:  Front Neurol       Date:  2018-02-15       Impact factor: 4.003

7.  The Role of Inflammation and Infection in Age-Related Neurodegenerative Diseases: Lessons From Bacterial Meningitis Applied to Alzheimer Disease and Age-Related Macular Degeneration.

Authors:  Lay Khoon Too; Nicholas Hunt; Matthew P Simunovic
Journal:  Front Cell Neurosci       Date:  2021-03-26       Impact factor: 5.505

8.  Impaired functions of macrophage from cystic fibrosis patients: CD11b, TLR-5 decrease and sCD14, inflammatory cytokines increase.

Authors:  Karin Simonin-Le Jeune; André Le Jeune; Stéphane Jouneau; Chantal Belleguic; Pierre-François Roux; Marie Jaguin; Marie-Thérèse Dimanche-Boitre; Valérie Lecureur; Caroline Leclercq; Benoît Desrues; Graziella Brinchault; Jean-Pierre Gangneux; Corinne Martin-Chouly
Journal:  PLoS One       Date:  2013-09-30       Impact factor: 3.240

9.  Soluble CD163 as a marker of macrophage activity in newly diagnosed patients with multiple sclerosis.

Authors:  Morten Stilund; Ann-Kathrin Reuschlein; Tove Christensen; Holger Jon Møller; Peter Vestergaard Rasmussen; Thor Petersen
Journal:  PLoS One       Date:  2014-06-02       Impact factor: 3.240

Review 10.  The Potentials of Melatonin in the Prevention and Treatment of Bacterial Meningitis Disease.

Authors:  Dong Zhang; Shu Xu; Yiting Wang; Guoqiang Zhu
Journal:  Molecules       Date:  2021-03-05       Impact factor: 4.411

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.